Estrogen receptor 1 mRNA is a prognostic factor in ovarian carcinoma: determination by kinetic PCR in formalin-fixed paraffin-embedded tissue.

Epidemiological and cell culture studies indicate that ovarian carcinoma growth is dependent on estrogen stimulation. However, possibly due to the lack of a reliable biomarker that helps to select patients according to prognostically relevant estrogen receptor (ER) levels, clinical trials using anti-estrogenic therapeutics in ovarian carcinoma have had inconsistent results. Therefore, we tested if ER expression analysis by a quantitative method might be useful in this regard in formalin-fixed paraffin-embedded (FFPE) tissue. In a study group of 114 primary ovarian carcinomas expression of estrogen receptor 1 (ESR1) mRNA was analyzed using a new method for RNA extraction from FFPE tissue that is based on magnetic beads, followed by kinetic PCR. The prognostic impact of ESR1 mRNA expression was investigated and compared to ERalpha protein expression as determined by immunohistochemistry. In univariate survival analysis the expression level of ESR1 mRNA was a significant positive prognostic factor for patient survival (hazard ratio (HR) 0.230 (confidence interval (CI) 0.102-0.516), P=0.002). ERalpha protein expression was correlated to ESR1 mRNA expression (P=0.0001); however, ERalpha protein expression did not provide statistically significant prognostic information. In multivariate analysis, ESR1 mRNA expression emerged as a prognostic factor, independent of stage, grade, residual tumor mass, age, and ERalpha protein expression (HR 0.227 (CI 0.078-0.656), P=0.006). Our results indicate that the determination of ESR1 levels by kinetic PCR may be superior to immunohistochemical methods in assessment of biologically relevant levels of ER expression in ovarian carcinoma, and is feasible in routinely used FFPE tissue.

[1]  Proceedings of the Cambridge Philosophical Society , 2022 .

[2]  C. Redmond,et al.  Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Smyth,et al.  Oestrogen receptor expression and the effects of oestrogen and tamoxifen on the growth of human ovarian carcinoma cell lines. , 1990, British Journal of Cancer.

[4]  O. Kallioniemi,et al.  Steroid receptors and Ki‐67 reactivity in ovarian cancer and in normal ovary: Correlation with dna flow cytometry, biochemical receptor assay, and patient survival , 1990, The Journal of pathology.

[5]  K. Hatch,et al.  Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A gynecologic oncology group study of second‐line therapy in 105 patients , 1991, Cancer.

[6]  A. Godwin,et al.  Spontaneous transformation of rat ovarian surface epithelial cells: association with cytogenetic changes and implications of repeated ovulation in the etiology of ovarian cancer. , 1992, Journal of the National Cancer Institute.

[7]  W. Sauerbrei,et al.  Steroid receptors in ovarian carcinoma: Immunohistochemical determination may lead to new aspects , 1993 .

[8]  G. Wampler,et al.  Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Smyth,et al.  Growth inhibition of oestrogen receptor-positive human ovarian carcinoma by anti-oestrogens in vitro and in a xenograft model. , 1994, European journal of cancer.

[10]  S. Howell,et al.  Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines. , 1994, British Journal of Cancer.

[11]  G. Scambia,et al.  Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy. , 1995, British Journal of Cancer.

[12]  A. Fattorossi,et al.  Tamoxifen synergizes the antiproliferative effect of cisplatin in human ovarian cancer cells: enhancement of DNA platination as a possible mechanism. , 1996, Cancer letters.

[13]  K. Hatch,et al.  Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report. , 1996, Gynecologic oncology.

[14]  W. Murdoch.  OVARIAN SURFACE EPITHELIUM, OVULATION AND CARCINOGENESIS , 1996, Biological reviews of the Cambridge Philosophical Society.

[15]  F. Akiyama,et al.  Toward the development of a universal grading system for ovarian epithelial carcinoma , 1998, Cancer.

[16]  S. Mok,et al.  Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[17]  C K Osborne,et al.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Shuk-Mei Ho,et al.  Expression of human estrogen receptor-α and -β, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells , 1999 .

[19]  K. Münstedt,et al.  Steroid hormone receptors and long term survival in invasive ovarian cancer , 2000, Cancer.

[20]  T. Tamaya,et al.  Clinical Significance of Expression of Estrogen Receptor α and β mRNAs in Ovarian Cancers , 2000, Oncology.

[21]  C. Tropé,et al.  Tamoxifen in the treatment of recurrent ovarian carcinoma. , 2000, European journal of cancer.

[22]  M. Thun,et al.  Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. , 2001, JAMA.

[23]  H. Gabra,et al.  CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  Tatyana Chernova,et al.  Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease , 2002, Nature.

[25]  D. Wilkinson.  Gene Expression Patterns , 2002, Brain Research.

[26]  M. Gore,et al.  Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis. , 2002, The Lancet. Oncology.

[27]  P. Hartge,et al.  Menopausal hormone replacement therapy and risk of ovarian cancer. , 2002, JAMA.

[28]  H. Katabuchi,et al.  Cell biology of human ovarian surface epithelial cells and ovarian carcinogenesis , 2003, Medical Electron Microscopy.

[29]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[30]  P. Pujol,et al.  Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. , 2004, Endocrine-related cancer.

[31]  R. Hornung,et al.  Analysis of potential prognostic factors in 111 patients with ovarian cancer. , 2004, Cancer letters.

[32]  D. Burns,et al.  Estrogen receptor-alpha mediates gene expression changes and growth response in ovarian cancer cells exposed to estrogen. , 2005, Endocrine-related cancer.

[33]  R. Cheng,et al.  Profiling estrogen-regulated gene expression changes in normal and malignant human ovarian surface epithelial cells , 2005, Oncogene.

[34]  D. Rosen,et al.  Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. , 2005, Gynecologic oncology.

[35]  Michael Gnant,et al.  Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial , 2005, The Lancet.

[36]  P. Hartge,et al.  Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort. , 2006, Journal of the National Cancer Institute.

[37]  M. Bookman,et al.  GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG-lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  D. Katsaros,et al.  The relationship of insulin-like growth factor-II, insulin-like growth factor binding protein-3, and estrogen receptor-alpha expression to disease progression in epithelial ovarian cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  I. Jacobs,et al.  Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study. , 2007, Oncology reports.

[40]  G. Sauter,et al.  Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer , 2007, Nature Genetics.

[41]  Andreas Makris,et al.  Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients , 2008, Breast Cancer Research and Treatment.

[42]  J. Ringman,et al.  Innate immunity and transcription of MGAT-III and Toll-like receptors in Alzheimer's disease patients are improved by bisdemethoxycurcumin , 2007, Proceedings of the National Academy of Sciences.

[43]  F. Tas,et al.  The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer , 2007, Medical oncology.

[44]  G. Colditz,et al.  A prospective study of postmenopausal hormone use and ovarian cancer risk , 2006, British Journal of Cancer.

[45]  H. Gabra,et al.  Antiestrogen Therapy Is Active in Selected Ovarian Cancer Cases: The Use of Letrozole in Estrogen Receptor–Positive Patients , 2007, Clinical Cancer Research.

[46]  J. Huober,et al.  Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6). , 2007, Gynecologic oncology.

[47]  S. Rubin,et al.  Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[49]  H. Moch,et al.  Oestrogen receptor gene (ESR1) amplification is frequent in endometrial carcinoma and its precursor lesions , 2008, The Journal of pathology.

[50]  N. Pavlidis,et al.  Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial , 2009, Breast Cancer Research and Treatment.

[51]  S. Leung,et al.  Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies , 2008, PLoS medicine.

[52]  H. Ngan,et al.  Estrogen Receptor Subtypes in Ovarian Cancer: A Clinical Correlation , 2008, Obstetrics and gynecology.